HoldsUp

Huberman Lab · 2026-08-03 · Andrew Huberman (host), Matthew (Max) Krummel

How Your Immune System Works & How to Improve It | Dr. Max Krummel

54 research-tied claims examined: 7 contradicted 2 overstated 7 context 37 supported 1 unverified

7 Needs context
0:12:35Matthew (Max) Krummelneeds contextmoderate

For the first six months of life, the human immune system is relatively poor at being trained on antigens.

"One of them is for the first 6 months or so, your immune system is pretty poor at being trained on things. And it's presumably we presume that for those first 6 months that's because your body's developing so fast that if you were to have a super active immune system, you might actually find yourself attacking yourself." (said at 0:12:35)

The claim captures the general biological rationale of early infant immunology but needs context. During early infancy (the first several months of life), the immune system is skewed toward immune tolerance, characterized by heightened naive CD4+ conversion to regulatory T cells (Tregs), dampened Th1 and cytotoxic effector responses, reduced memory formation, and reliance on maternal antibodies to avoid damaging inflammatory and autoimmune reactions to rapid physiological growth and colonizing commensals. However, characterizing the system as simply 'poor at being trained' is an oversimplification: infant immune systems can and do mount antigen-specific responses to vaccines (such as HepB, DTaP, and pneumococcal vaccines administered from birth and 2 months onward), though they typically require multiple doses or adjuvants due to this physiological tolerogenic bias.

0:40:10Matthew (Max) Krummelneeds contextmoderate

Developing T cells have a theoretical receptor diversity potential on the order of 10 to the 11th power.

"And so the T cells that come in there, they're T cells that are developing and they each have a possible 10 to the 11th different kinds of receptors to smell different things." (said at 0:40:10)

The speaker's estimate of 10^11 potential T-cell receptor (TCR) variants captures the vast diversity of the T-cell repertoire, though theoretical combinatorial potential and realized repertoire sizes differ. Through V(D)J recombination and junctional diversity during thymocyte development, theoretical TCR diversity is estimated to exceed 10^15 to 10^20 possible sequences. In practice, due to thymic selection and cellular constraints, an individual human maintains an estimated circulating naive TCR repertoire of approximately 10^8 (100 million) distinct clonotypes out of an organismal pool of roughly 10^11–10^12 total T cells.

0:49:50Matthew (Max) Krummelneeds contextmoderate

During sleep, circulating immune cells clear out of the bloodstream and migrate back into the bone marrow.

"and one of them is that a lot of your immune cells clear back to the bone marrow." (said at 0:49:50)

Circulating immune cells undergo pronounced circadian and sleep-dependent redistribution, but the specific destination and timing vary by cell subset and species. In humans, nocturnal sleep promotes the homing of naive and memory T cells to lymph nodes (facilitating immune surveillance and memory formation), whereas redistribution of certain leukocyte subsets to the bone marrow via CXCR4 upregulation is driven by daytime cortisol peaks during the active phase. In contrast, nocturnal animal models (e.g., mice) clear leukocytes and aged neutrophils back into the bone marrow during their rest/sleep phase (the light period). Thus, while sleep and circadian cycles govern immune cell clearance from circulation to tissues including lymph nodes and bone marrow, attributing generalized bone marrow clearance directly to human sleep conflates rest-phase rodent findings and specific leukocyte subset kinetics.

  • context: The contribution of sleep to the neuroendocrine regulation of rhythms in human leukocyte t… (Seminars in immunopathology 2022) · cited 53x in the literature
    "In addition, sleep increases levels of immunosupportive mediators, such as aldosterone and growth hormone, which are assumed to promote T-cell homing to lymph nodes, thus facilitating the initiation of adaptive immune responses during sleep. Taken together, sleep-wake behavior with its unique neuroendocrine changes regulates human leukocyte traffic with overall immunosupportive effects during nocturnal sleep. In contrast, integrin de-activation and redistribution of certain leukocytes to the bone marrow during daytime activity presumably serves immune regulation and homeostasis." (abstract, conclusions, passage verified)
    pubmedfull study (doi)
0:52:46Matthew (Max) Krummelneeds contextmoderate

Macrophages reside in the eye where they function to clear debris from the lens.

"I always like the story that that there's macrophages, immune cells, in your eye that are basically clearing the clearing the lens." (said at 0:52:46)

The claim refers to the established developmental role of ocular macrophages in clearing transient embryonic vascular structures and cellular debris surrounding the developing lens (such as the tunica vasculosa lentis and hyaloid vessels) to establish an unobstructed optical path for vision. However, the mature lens itself is an encapsulated, avascular, and immune-privileged structure lacking resident macrophages; the clearance of light-scattering organelles inside maturing lens fiber cells is mediated by cell-autonomous degradation pathways (e.g., autophagy and enzymatic organelle breakdown) rather than phagocytosis by intra-lenticular macrophages.

1:03:08Matthew (Max) Krummelneeds contexthigh

CAR-T cell therapies involve engineering T cells with specialized receptors to target tumors, but often fail in patients due to the immune system shutting down or cells failing to eliminate the tumor.

"these things called CAR-Ts, and Alex would have told you about these where you engineer your T cells and you get you give them special receptors that can get them to go into to eliminate tumors. But for whatever reason, they haven't worked in patients. They haven't worked. They haven't worked. They haven't worked. And T cell—the immune system gets turned off. These cells don't make it. They don't fail—they fail to eliminate the tumor." (said at 1:03:08)

Chimeric antigen receptor (CAR) T-cell therapy involves genetically modifying a patient's T cells to express synthetic receptors targeted against tumor antigens. The speaker correctly identifies key biological failure mechanisms: T-cell exhaustion, limited cell persistence, and an immunosuppressive tumor microenvironment ('the immune system gets turned off') frequently prevent sustained tumor eradication. However, the blanket assertion that they 'haven't worked in patients' requires important context: CAR-T therapies have achieved remarkable, durable responses and multiple FDA approvals for hematologic malignancies (e.g., leukemias, lymphomas, myeloma), whereas the limited efficacy and failure mechanisms described by the speaker apply predominantly to solid tumors and relapsed/refractory non-responders.

1:07:18Matthew (Max) Krummelneeds contexthigh

CRISPR gene editing technology was discovered through research on how bacteria use enzymes to remember foreign genetic sequences and defend against invaders.

"CRISPR, you know, that was people were studying like how do bacteria defend against other bacteria? Well, they use this—it turns out there's this enzyme and it remembers the sequence of this one bacteria that has come and invaded you before and then can like modify the genome and get rid of it and like kill it." (said at 1:07:18)

The speaker accurately describes the core adaptive immune mechanism of CRISPR-Cas—in which bacteria capture and store fragments of foreign genetic material (spacers) to recognize and enzymatically cleave matching invaders upon reinfection, a mechanism subsequently adapted into gene-editing tools. However, the speaker incorrectly describes the system as defending against 'other bacteria'; CRISPR naturally functions primarily to defend bacteria against bacteriophages (viruses) and mobile genetic elements such as plasmids.

2:12:05Matthew (Max) Krummelneeds contextmoderate

There are approximately seven or eight distinct subtypes of asthma, with variations including eosinophil-predominant or neutrophil-predominant profiles.

"Is there only one form of asthma? That's no, there's actually definitely there's seven or eight. And they have and that's why some people are, you know, like can take the inhalers and it works and other people can't. Some people they're very like chlorine sensitive. They go to a pool and it and and it's just like cold sensitive. So, there's there's variations on what sets up that inflammatory focus. And I would call it like an archetype. Some of them have lots of cells called eosinophils. Other ones have lots of cells called neutrophils." (said at 2:12:05)

Asthma is well established to be a heterogeneous umbrella syndrome rather than a single disease, comprising distinct clinical phenotypes and biological endotypes that explain variations in treatment responsiveness (e.g., standard steroid inhalers vs. targeted biologics). Classically, inflammatory subtyping categorizes asthma into four cytological phenotypes based on sputum/blood cell profiles: eosinophilic (Type 2-high), neutrophilic (non-Type 2), mixed granulocytic, and paucigranulocytic. While comprehensive cluster analyses (such as those from the SARP, ADEPT, and U-BIOPRED cohorts) and clinical taxonomies frequently delineate multiple sub-clusters and clinical phenotypes (ranging from 4 to 8+ distinct groups when incorporating age of onset, atopy, obesity, irritant/occupational triggers, and molecular signatures), there is no single universally standardized classification fixing the number of asthma subtypes at precisely seven or eight.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.